Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

AICAR (Acadesine) iconAICAR (Acadesine)Small moleculeNo amino acid sequence. Icon reflects category theme only.

AICAR (Acadesine)

Beginner tier: 10 mg, daily · preclinical extrapolation

MetabolicResearch
~2-3 hours half-life·Injection

Also known as: acadesine, AICA ribonucleoside, ZMP precursor

Sedentary mice ran 44% farther after receiving AICAR for just a few weeks. That 2008 Cell paper by Narkar and colleagues turned this cardiac surgery leftover into the most talked-about "exercise in a pill" candidate in metabolic research. AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, also called acadesine) activates AMP-activated protein kinase, the same metabolic switch that fires during exercise. WADA banned it in 2009. The catch is stark: those mouse doses were 500x higher than what the community injects subcutaneously. No human efficacy trial exists for this route. Users still run short 14-day cycles for metabolic support and fat oxidation, but expectations should match that evidence gap.

What Is AICAR (Acadesine)?

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, also known as acadesine, CAS 2627-69-2) is a cell-permeable nucleoside analog that directly activates AMPK, the same energy sensor that exercise triggers. The Narkar study in Cell [1] made headlines: 44% boost in running endurance without a single training session. It enters cells through adenosine transporters. Once inside, adenosine kinase converts it into ZMP, a compound that mimics AMP and directly activates AMPK. That triggers the same metabolic cascades that exercise does: fatty acid oxidation ramps up, glucose uptake increases, mitochondrial biogenesis kicks in.

The compound had an earlier career in cardiology. PeriCor Therapeutics tested it intravenously in over 4,000 cardiac surgery patients during the 1990s [2]. That program ended after a Phase III futility analysis in 2010. Interest shifted entirely toward exercise mimicry, and AICAR became notorious in professional cycling. Reports during the 2013 and 2019 Tour de France alleged riders were using powdered AICAR as a performance booster. WADA had already placed it on the Prohibited List in 2009.

Community users inject 10 to 50 mg subcutaneously in short 14-day cycles. The dose gap deserves stating plainly. Mouse efficacy studies used 300 to 500 mg/kg per day. For a 70 kg human, community doses land around 0.14 to 0.7 mg/kg. That is a 500 to 3,500x difference. A 2021 systematic review in Cells [3] confirmed AICAR has documented AMPK-independent effects too, which complicates the picture further. Research status sits at well-researched for the mechanism, but zero completed human efficacy trials exist for subcutaneous administration.

How AICAR (Acadesine) Works

AICAR enters cells through adenosine transporters because its structure looks enough like adenosine to use the same channels. Once intracellular, adenosine kinase phosphorylates it into ZMP (also called AICA ribotide). ZMP binds the gamma subunit of AMPK allosterically, and the kinase complex activates. This is the exact energy-sensing pathway that fires when ATP drops during exercise and AMP accumulates.

Downstream, activated AMPK hits several targets simultaneously. It pushes GLUT4 to the cell membrane, pulling glucose into skeletal muscle independent of insulin. It phosphorylates acetyl-CoA carboxylase, which drops malonyl-CoA levels and unlocks mitochondrial fatty acid beta-oxidation. AMPK also turns on PGC-1alpha signaling. That drives mitochondrial biogenesis and shifts muscle fiber type toward slow-twitch (type I); the same remodeling happens with endurance training over months.

AICAR also acts through pathways that have nothing to do with AMPK. ZMP inhibits fructose-1,6-bisphosphatase and other enzymes in purine biosynthesis. It competes with adenosine for nucleoside transporters, raising extracellular adenosine concentrations and activating adenosine receptor signaling. A 2018 study confirmed AICAR activates tumor suppressors LATS1 and LATS2 through an AMPK-independent mechanism entirely [4]. These off-target effects matter because they make predicting what AICAR actually does at any given dose much harder.

AICAR (Acadesine) Benefits

  • AICAR benefits center on AMPK activation and the metabolic cascades that follow from it.
  • Activates AMPK at the cellular level, mimicking the metabolic switch that exercise flips. This is the best-documented effect across both animal and in vitro research.
  • Increases fatty acid oxidation and glucose uptake in skeletal muscle through GLUT4 translocation. That process happens independent of insulin, which is why metabolic syndrome researchers took notice early.
  • Boosted treadmill endurance by 44% in sedentary mice over roughly four weeks (Narkar et al., Cell 2008)[1]. A 2025 FASEB BioAdvances study (PMC11886611) confirmed similar gains in aged mice, reversing age-related exercise decline.
  • Promotes mitochondrial biogenesis through PGC-1alpha signaling. This is the same pathway that months of endurance training activates.
  • Community users (estimated 100 to 300 active) report subtle improvements in fasted cardio and exercise recovery during 14-day cycles, though separating signal from placebo at these doses is genuinely difficult.
  • A 2025 study showed AICAR prevented and reversed diabetic polyneuropathy in animal models through mitophagy regulation [5]. That therapeutic angle gets less attention than it probably deserves.

AICAR (Acadesine): Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 7 key studies·Research only

Strong AMPK activator with well-documented metabolic effects in animals.

Dosing studied: 300-500 mg/kg/day SC in mice (exercise mimetic studies). Human IV: up to 210 mg/kg single dose tolerated in clinical trials. No established SC dose in humans.
Read the evidence (key study, limitations)

No completed human efficacy trials for SC use. IV data from cardiac surgery trials showed safety but not efficacy for the studied indication.

Key Study

Narkar et al. 2008 (PMID 18674809): AICAR increased running endurance 44% in sedentary mice. Confirmed in aged mice by 2025 FASEB BioAdvances study (PMC11886611) showing reversed age-related exercise decline.

Limitations

All efficacy data is from animal models. The gap between mouse doses (300-500 mg/kg) and community SC doses (0.14-0.7 mg/kg for a 70 kg human) is enormous: roughly 500-3,500x lower. No human PK data exists for SC administration. Significant AMPK-independent effects complicate interpretation of what AICAR actually does at any given dose.

Community Experience
Weak
2.5/5
Based on small: estimated 100-300 active community users. Far fewer reports than compounds like BPC-157 or semaglutide.

Niche compound with a small but dedicated following.

Community dosing: 10-50 mg/day SC for 10-14 day cycles
Read the reports (what users report 4, common issues 5)

Most users treat it as a metabolic booster or "rest day recovery" tool rather than a primary exercise replacement. Mixed reports on whether subcutaneous doses produce meaningful effects.

What users report (4)
  • Subtle increase in energy and warmth within first few days
  • Improved exercise recovery on rest days
  • Slight fat loss over a 2-week cycle when combined with training
  • Better fasted cardio performance reported by some users
Common issues (5)
  • Expensive per cycle: a single 50 mg vial lasts 2-5 days depending on dose
  • Effects are subtle and hard to distinguish from placebo at community doses
  • Fatigue and temporary strength drop in first 2-3 days
  • Uric acid spikes caught some users off guard
  • Limited community sample: far fewer reports than mainstream peptides
Partially Aligned

Science and community agree AICAR activates AMPK and affects metabolism. But the dose gap is the elephant in the room: mouse studies use 300-500 mg/kg, while humans inject 10-50 mg total. That's a >500x difference even after basic allometric scaling. Community effects at these doses may be real but are likely much weaker than what the mouse data suggests. The science can't confirm or deny community-dose efficacy because nobody has studied it.

AICAR (Acadesine) Dosage Guide

ExtrapolatedDose extrapolated from animal exercise physiology studies; no approved human dosing
LevelDose / InjectionFrequency
Beginner10 mg
DailyTrack
Moderate25 mg
DailyTrack
Aggressive50 mg
Note:

AICAR comes as a lyophilized powder, typically in 50 mg vials. Add 2 mL of bacteriostatic water and you get 25 mg/mL concentration.

Reconstitution math: at 25 mg/mL, a 10 mg dose is 0.4 mL (40 units on an insulin syringe). A 25 mg dose is 1.0 mL (100 units, a full syringe). The 50 mg aggressive dose uses the entire 2 mL vial per shot; split across two sites or grab a larger syringe.

Morning dosing, fasted, aligns with natural metabolic rhythms and the fasted state amplifies AMPK signaling. On training days, inject 30 to 60 minutes before cardio.

Cost adds up fast and that's the thing most beginners miss. A 14-day beginner cycle at 10 mg/day runs through about 3 vials ($150 to $195). The intermediate 25 mg/day protocol burns 7 vials ($350 to $455). Budget for the full course.

Hydration matters here more than with most compounds. Your kidneys are doing the clearing. Three liters of water daily is the community standard during active cycles. AICAR is not a peptide; it's a small molecule nucleoside analog. It degrades with moisture faster than typical peptides, so keep lyophilized powder dry.

Cycling Protocol

On Period
2 weeks
Off Period
6 weeks

AICAR should not be used for longer than 14 consecutive days due to accumulation toxicity and renal stress risk. Allow at least 4-8 weeks of washout between cycles. No more than 3 cycles per year. Monitor kidney function and uric acid levels during use.

Calculate your AICAR (Acadesine) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

AICAR (Acadesine) Protocols by Goal

beginnerCommunity14 days max
Introduction
Wk 1-2
10 mg · Daily · Subcutaneous

Expected: Subtle increase in energy, mild improvement in fasted exercise tolerance. Fat loss effects minimal at this dose over 2 weeks.

Monitor: Check uric acid and basic metabolic panel before starting and after the cycle.

How to Inject AICAR (Acadesine)

  1. 1
    Reconstitute one 50 mg vial with 2 mL bacteriostatic water

    Aim the stream at the glass wall, not directly into the powder. Swirl gently until fully dissolved. Solution should be clear and colorless.

  2. 2
    Draw your dose with a 29 or 30 gauge insulin syringe

    At 25 mg/mL concentration: 10 mg equals 40 units, 25 mg equals 100 units (full syringe), 50 mg equals 200 units (use two syringes or a 3 mL syringe for the full vial).

  3. 3
    Clean the injection site with an alcohol swab

    Abdomen (two inches from the navel), thigh, or upper arm all work. Rotate sites each day to prevent lipohypertrophy.

  4. 4
    Step 4

    Pinch the skin and insert the needle at a 45 to 90 degree angle. Inject slowly over 15 to 30 seconds. For larger volumes (1 mL or more), steady pressure over 30 to 60 seconds reduces lumps. Remove needle and apply light pressure with a cotton ball.

  5. 5
    For doses above 1 mL, split between two injection sites

    Warming the syringe in your hand for 30 seconds before injecting makes it more comfortable.

  6. 6
    Store reconstituted vials at 2 to 8 degrees Celsius

    Use within 14 days. Do not freeze the reconstituted solution.

Timing: morning, fasted. On training days, 30 to 60 minutes before exercise. Stay well-hydrated (3+ liters daily) throughout your cycle.

Mixing your own vial? Use the AICAR (Acadesine) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

AICAR (Acadesine) Stacking Protocols

Works With

Avoid

Metformin

Both activate AMPK. Stacking creates additive AMPK stimulation that may cause excessive glucose lowering or lactic acidosis. This is a pharmacological interaction, not a theoretical one.

Do not combine
Insulin / Sulfonylureas

AICAR improves insulin sensitivity and glucose uptake. Combined with insulin or insulin secretagogues, hypoglycemia risk increases significantly.

Do not combine
Dipyridamole / Adenosine receptor agonists

AICAR raises extracellular adenosine levels by competing for nucleoside transporters. Adenosine receptor agonists on top could amplify cardiovascular effects (hypotension, bradycardia).

Estimated Cost

Compounded
~$50-65 per 50 mg research-grade vial (2025-2026 pricing). A 14-day beginner cycle (10 mg/day) uses ~3 vials ($150-195). An intermediate cycle (25 mg/day) uses ~7 vials ($350-455). This makes AICAR one of the more expensive research peptides per cycle.

Pricing updated 2026-04-09

AICAR (Acadesine) Side Effects

Hyperuricemia is the side effect that demands the most attention. AICAR elevates uric acid levels, and at higher doses this can trigger gout flares with sudden joint pain and swelling. If that happens mid-cycle, check uric acid immediately. Don't push through it. Prophylactic allopurinol (100 to 300 mg daily) is commonly co-administered in community protocols running 25 mg or above.

Kidney stress is the second serious concern. AICAR and its metabolite ZMP are renally cleared. Even at community subcutaneous doses (10 to 50 mg/day), the kidneys carry the full clearance burden. The 14-day cycle limit exists specifically because of accumulation toxicity risk, not receptor desensitization. Creatinine trending upward on mid-cycle labs is a stop signal; don't wait for symptoms.

In the cardiac surgery IV trials [2], which used doses up to 210 mg/kg, researchers documented transient anemia and thrombocytopenia. Those doses dwarf community SC protocols. Monitoring CBC on aggressive cycles is still reasonable practice.

Hypoglycemia is a real possibility during fasted use. AMPK activation drives glucose uptake independent of insulin through GLUT4 translocation. Stacking fasted training with AICAR, or combining it with metformin, creates additive glucose-lowering. Keep glucose tabs on hand.

GI effects show up in some users: nausea, bloating, abdominal discomfort. These tend to be mild and dose-dependent. Injection site reactions (redness, swelling, lumps) are common, especially at higher volumes. Splitting a 1 to 2 mL dose across two sites reduces discomfort.

Fatigue in the first two to three days trips up newcomers. AMPK activation shifts metabolism toward fat oxidation and away from glycolytic power output. Feeling more tired rather than energized early on is normal. If that tiredness hasn't resolved by day four, lower the dose or stop the cycle.

One theoretical concern: chronic AMPK overactivation may promote muscle atrophy through FoxO3-mediated autophagy. This hasn't been documented at community doses. It is, however, the rationale behind keeping cycles short and washouts long.

Contraindications: pregnancy or breastfeeding (zero reproductive safety data), chronic kidney disease, active gout or hyperuricemia, hypoglycemia without medical supervision, children under 18, active malignancy (AMPK has context-dependent effects on tumor growth), and competitive athletes subject to WADA testing.

Common Issues & Solutions

Feeling more tired, not more energetic? That's common in the first 2-3 days. AMPK activation shifts your metabolism toward fat oxidation and away from glycolytic power output. If fatigue persists past day 4, drop the dose or stop the cycle.

Joint pain or swelling during a cycle? Check uric acid immediately: AICAR-induced hyperuricemia can trigger gout. Start allopurinol and hydrate aggressively. Don't push through joint pain on this compound.

Large injection volume at higher doses (1-2 mL SC) can cause lumps or discomfort. Split the dose across two injection sites or inject very slowly over 30-60 seconds. Warming the solution to room temperature before injecting helps.

Not noticing any effects at 10 mg/day? You're probably right: community doses are >500x below the animal study doses. The honest answer is that nobody knows if 10 mg SC does anything meaningful in humans. Consider whether the cost-benefit makes sense for you.

Blood sugar running low during fasted use? AICAR drives glucose uptake independent of insulin. If you're stacking fasted training with AICAR, keep glucose tabs or a quick carb source nearby, especially in the first few days.

Ask AI about this page

Ask AI for a second opinion on AICAR (Acadesine) dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: no reproductive safety data exists
  • Chronic kidney disease or impaired renal function: AICAR and ZMP are renally cleared and may worsen kidney stress
  • Active gout or hyperuricemia: AICAR elevates uric acid levels
  • Hypoglycemia or insulin-dependent diabetes without medical supervision: AMPK activation lowers blood glucose
  • Children and adolescents under 18: not studied in pediatric populations
  • Active malignancy: AMPK activation has context-dependent effects on tumor growth
  • Competitive athletes subject to WADA testing: AICAR has been on the Prohibited List since 2009
  • Hepatic impairment: adenosine kinase pathway primarily cleared via liver; pharmacokinetics not characterized in hepatic disease (PMID 34064363)

Drug Interactions

  • Metformin and other AMPK activators: additive AMPK stimulation may cause excessive glucose lowering or lactic acidosis risk; avoid stacking
  • Insulin and sulfonylureas: combined insulin-sensitizing effects increase hypoglycemia risk significantly
  • Allopurinol: commonly co-administered to manage AICAR-induced hyperuricemia; monitor uric acid levels
  • Adenosine receptor agonists (dipyridamole, regadenoson): AICAR raises extracellular adenosine, potentially amplifying cardiovascular effects
  • Anticoagulants: transient thrombocytopenia has been observed at high AICAR doses; monitor platelet counts
  • Nucleoside analog drugs (ribavirin, acyclovir): potential competition for nucleoside transporters may alter drug uptake
  • Dipyridamole / Adenosine receptor agonists

Product Quality

Recommended Monitoring

TestWhenTarget
Uric acidBaseline, day 7, and 1 week post-cycleBelow 7.0 mg/dL (male) / 6.0 mg/dL (female). Stop if above 9.0 mg/dL.
Basic metabolic panel (BUN, creatinine)Baseline, day 7, and 1 week post-cycleCreatinine within normal limits for your baseline. Any upward trend warrants stopping.
Fasting blood glucoseBaseline and day 770-100 mg/dL. Watch for symptoms below 70.
CBC (complete blood count)Baseline and post-cycle (advanced protocol only)Not listed
Uric acid

Hyperuricemia is the most common side effect. Catching elevated levels early prevents gout flares and renal complications.

Basic metabolic panel (BUN, creatinine)

AICAR and ZMP are renally cleared. Even at community doses, kidney stress is the primary safety concern.

Fasting blood glucose

AMPK activation drives insulin-independent glucose uptake. Hypoglycemia risk is real, especially if stacking with metformin or fasting protocols.

CBC (complete blood count)

Transient anemia and thrombocytopenia were observed at high IV doses in clinical trials. Unlikely at community SC doses but worth checking on aggressive protocols.

AICAR (Acadesine) Before and After

Days 1-3

AMPK activation begins at the cellular level. No outward changes are expected yet. Some users report a subtle increase in energy or warmth. Monitor injection sites for reactions.

Days 4-7

Fatty acid oxidation rates start to increase. Mild improvements in exercise tolerance may become noticeable. Blood glucose may trend slightly lower in insulin-resistant subjects. Uric acid levels should be monitored.

Days 8-10

Peak metabolic effects within a 14-day cycle. Endurance and fat metabolism improvements are most pronounced. Animal data showed 44% endurance gains at comparable timepoints. Body composition shifts may become measurable.

Days 11-14

Final days of the recommended cycle window. Cumulative AMPK activation should be at its highest. Discontinue at day 14 to prevent accumulation-related side effects. Benefits persist for several days after the last dose.

Post-cycle
weeks 1-8 off

Metabolic benefits gradually return to baseline over 1-2 weeks. AMPK activity normalizes as ZMP clears. Maintain exercise and dietary habits gained during the cycle. Wait at least 4-8 weeks before considering another cycle.

What to Expect

Days 1 through 3 (AMPK activation begins): ZMP starts accumulating inside cells within hours of each injection. AMPK phosphorylation ramps up and metabolic gene expression begins shifting. Some users pick up a subtle warmth or mild energy bump. Others actually feel more tired, which tracks; your metabolism is being pushed toward fat oxidation and away from quick glycolytic output. Injection site redness is common and not a reason to stop.

Days 4 through 7 (Metabolic shift): Fatty acid oxidation rates climb. GLUT4 translocation means greater glucose uptake in muscle tissue. Mitochondrial biogenesis genes are being upregulated. Community reports point to better exercise tolerance, especially during cardio. Blood sugar may trend lower. Get uric acid labs at day 7 if you're running 25 mg or above; this is where side effects start showing up on paper before you feel them.

Days 8 through 14 (Peak effects): Strongest window in a 14-day cycle. Cumulative AMPK activation hits its highest point. In aged mice, measurable improvements in exercise performance and muscle gene expression showed up at this stage. Community users call this the period where the protocol feels like it's working. Stop at day 14. This is also the highest-risk window for uric acid spikes and kidney stress, so monitoring matters most right now.

Weeks 1 through 2 off (Washout begins): ZMP clears within days given the 2 to 3 hour plasma half-life. AMPK activity drifts back to baseline. Mitochondrial adaptations from the cycle (biogenesis, fiber type shifts) may hang around a bit longer if you kept training. Most users feel benefits tapering over one to two weeks.

Weeks 3 through 8 off (Full washout): Complete metabolic normalization. Most users report feeling back to baseline by week three or four. This washout period exists for kidney recovery and uric acid normalization, not because AMPK needs a rest. Four weeks minimum before another cycle; longer is better for renal health.

Detailed Timeline: Science vs Community

Days 1-3
Science

Intracellular ZMP accumulates and AMPK phosphorylation increases within hours of each dose. Metabolic gene expression starts shifting.

Community

Some users notice a subtle warmth or energy bump. Others feel more tired than usual as metabolism shifts. Injection site redness is common.

Days 4-7
Science

Fatty acid oxidation rates should be increasing. GLUT4 translocation drives greater glucose uptake in muscle. Mitochondrial biogenesis genes are upregulated.

Community

Improved exercise tolerance starts showing up, especially in cardio. Blood sugar may trend lower. Some fat loss visible in users with good baseline conditioning.

Days 8-14
Science

Maximum cumulative AMPK activation. In aged mice, significant improvements in exercise performance and muscle gene expression were measurable by this point.

Community

Best endurance gains reported in this window. Body composition improvements peak. This is where most users feel the protocol is "working." Stop at day 14.

Weeks 1-2 off
Science

ZMP clears within days given the 2-3 hour half-life. AMPK activity returns to baseline. Metabolic adaptations from the cycle (mitochondrial biogenesis) may persist longer.

Community

Benefits taper off over 1-2 weeks. Some users report maintained endurance if they kept training during the cycle. Energy and body composition gradually return to baseline.

Weeks 3-8 off
Science

Complete metabolic normalization. Any mitochondrial gains from a 14-day cycle are likely modest and transient without ongoing exercise stimulus.

Community

Most users feel back to baseline by week 3-4. This is the minimum recommended washout before another cycle. Longer is better for kidney recovery.

Pharmacokinetics

Half-Life
2.5h
Bioavailability
SC: not formally determined in humans; IV bioavailability is 100% (reference route in clinical trials)
Tmax
~30-60 minutes (SC, estimated)
Data Confidence
low

Source: Estimated from clinical pharmacokinetic data in cardiac surgery patients. AICAR has a short plasma half-life due to rapid cellular uptake and phosphorylation to ZMP. Intracellular ZMP persists longer (PMID 7818622).

Pharmacokinetics: Active Dose Over Time

t½ = ~2-3 hours (plasma)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider AICAR (Acadesine)

  • Researchers studying AMPK-mediated metabolic regulation
  • Adults with metabolic syndrome or insulin resistance (research context only)
  • Individuals investigating exercise mimetic compounds for periods of immobility
  • Scientists studying diabetic neuropathy and mitophagy pathways
  • Anti-doping researchers developing detection methodologies

Related Peptides

What Changed for AICAR (Acadesine)

  1. Evidence

    Corrected Oct 20, 2026: AICAR's research stage is phase 3, not 2; IV acadesine had a published phase 3 (RED-CABG), per PubMed (PMID 22782417).

    Before: Phase 2 After: Phase 3 (RED-CABG, IV acadesine in bypass surgery, PMID 22782417)

    What this does not mean: No new study was published, and the dose tiers are unchanged. RED-CABG gave acadesine (AICAR) IV during bypass surgery and stopped for futility after 3,080 of a planned 7,500 patients. It did not test subcutaneous use.

    Source: JAMA 2012, Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial (Newman et al.; registered as phase 3, NCT00872001) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 7, 20267 Citations

References

  1. [1]AMPK and PPARdelta agonists are exercise mimetics (Narkar et al., Cell 2008) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]An initial multicenter randomized controlled trial on the safety and efficacy of acadesine in patients undergoing CABG surgery (Anesth Analg 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review (Cells 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]AICAR Antiproliferative Properties Involve the AMPK-Independent Activation of the Tumor Suppressors LATS 1 and 2 (Mol Ther 2018) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Administration of AICAR Prevents and Reverses Diabetic Polyneuropathy by Regulating Mitophagy (Int J Mol Sci 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Metabolic modulators of the exercise response: doping control analysis of GW501516 and AICAR (Drug Test Anal 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Room temperature up to 1 month, refrigerated at 2-8°C for up to 2 years. Protect from moisture.
After Reconstitution
Refrigerate at 2-8°C, use within 14 days. Do not freeze.
Temperature
2-8°C (36-46°F) after reconstitution

Frequently Asked Questions

AICAR (acadesine) is an adenosine analog that activates AMP-activated protein kinase (AMPK), the same energy-sensing pathway triggered by exercise and caloric restriction. Narkar and colleagues showed a 44% increase in running endurance in sedentary mice without any training (Cell, PMID 18674809). The compound mimics the metabolic effects of aerobic exercise at the cellular level.

Beginner: 10 mg subcutaneous daily. Moderate: 25 mg daily. Aggressive: 50 mg daily. Cycle length is typically 4-6 weeks. Clinical studies used IV infusion at much higher doses (100+ mg/kg), but community subcutaneous protocols use milligram-range doses based on extrapolated animal data.

Hypoglycemia risk is the primary safety concern due to direct AMPK activation and increased glucose uptake. Lactic acidosis has occurred at clinical IV doses. Community-reported effects at subcutaneous doses include fatigue, mild GI discomfort, and exercise-like muscle soreness. WADA has banned AICAR since 2009.

No. AICAR (acadesine) reached Phase 3 trials for reduction of ischemic complications during coronary artery bypass surgery but was not approved. It remains a research compound. WADA prohibits its use in competitive athletics, and detection methods exist for anti-doping testing.

AICAR (Acadesine) typically comes in 50mg vials. Add 2mL of bacteriostatic water to the vial. Use the free calculator for exact syringe units based on your desired dose.